Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy
Immune checkpoint blockade therapies that target CTLA-4 and PD-1/PD-L1 have ushered in a new era of cancer treatment. Nevertheless, a significant proportion of patients demonstrated primary or acquired resistance. Harnessing gut microbiota has been an emerging novel therapeutic strategy to overcome...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , , , , |
|---|---|
| Hōputu: | Revisão |
| Reo: | Ingarihi |
| I whakaputaina: |
2020
|
| Urunga tuihono: | https://doi.org/10.1016/j.coph.2020.06.004 |
| Ngā Tūtohu: |
Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|